S-1: cbdMD S-1 Filing: 2M Shares for Resale, Dilution Ahead

cbdMD, Inc. registers up to 2,000,000 common shares for resale by selling shareholders, stemming from recent Series C Preferred Stock conversions, with no new proceeds for the company.

Summary

• The company filed an S-1 registration statement for the potential resale of up to 2,000,000 shares of common stock by identified selling shareholders.
• These shares are issuable upon conversion of Series C Convertible Preferred Stock, which was sold and issued to the Selling Shareholders on December 18, 2025, for aggregate gross proceeds of $2,250,000.
• The company will not receive any proceeds from the sales of these common shares by the Selling Shareholders.
• The common stock is listed on the NYSE American under the symbol YCBD, with a last reported sales price of $0.8310 per share on January 20, 2026.
• The Series C Preferred Stock is convertible at an initial price of $2.25 per share, subject to adjustment, with a floor conversion price of $0.65 per share.
• Management reported progress in fiscal 2025, reducing GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025.
• The company successfully simplified its capital structure by converting Series A Convertible Preferred Stock and accrued dividends, regaining compliance with NYSE American listing standards.
• Momentum is noted in direct-to-consumer and wholesale businesses, with the Oasis brand showing quarterly growth and expanded distribution.
• Nearly $200,000 in corporate overhead savings have been identified for implementation in early 2026.
• Federal regulatory action in November 2025 poses a significant threat to the hemp industry, though Senator Wyden introduced the Cannabinoid Safety and Regulation Act (CSRA) in December 2025 to mitigate potential impacts.

Sentiment

Score: 5

Explanation: The filing is primarily a procedural S-1 for resale, which is neutral in itself. While it highlights some positive operational improvements (reduced operating loss, NYSE compliance) and recent capital raises from prior periods, it also reiterates the 'going concern' warning from auditors and significant regulatory risks. The potential for dilution from conversions is also a factor. The net effect is a mixed outlook, leaning towards neutral given the procedural nature and previously disclosed information.

Positives

• Reduced GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025, indicating improved operational efficiency.
• Successfully cleaned up the capital structure and regained compliance with NYSE American continued listing standards by converting Series A Convertible Preferred Stock.
• Reported sequential and year-over-year revenue increase in the fiscal fourth quarter of 2025, indicating business momentum.
• The Oasis brand, a hemp-derived THC beverage, is growing quarterly, adding distributors, and improving sell-through at retailers, expanding its presence across several states.
• Identified nearly $200,000 in corporate overhead savings to be implemented in early 2026, primarily from insurance renewals and professional fees.

Negatives

• The auditor's report (Cherry Bekaert LLP) contains an explanatory paragraph regarding the company's ability to continue as a going concern.
• The Oasis brand has been an earnings drag on the company's P&L due to investments in scaling, despite its growth.
• Federal regulatory action in November 2025 poses a significant threat to the hemp industry and the company's revenue bases, with no assurance the Cannabinoid Safety and Regulation Act will be enacted.
• The company will not receive any proceeds from the resale of the 2,000,000 shares of common stock by the Selling Shareholders.
• The issuance of shares upon conversion of Series B and Series C Preferred Stock, as well as the exercise of outstanding options, restricted stock awards, and warrants, will result in dilution to existing shareholders.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section and incorporated documents.
• Failure to satisfy NYSE American continued listing standards could result in de-listing, leading to a lack of trading market, reduced liquidity, decreased analyst coverage, and inability to obtain additional financing.
• Management has broad discretion over the use of proceeds from the initial sales of Series C Preferred Stock, which may not yield significant returns or enhance common stock value.
• The issuance of shares upon exercise of outstanding options, restricted stock awards, warrants, or the conversion of Series B and Series C Preferred Stock will cause immediate and substantial dilution to existing shareholders.
• The conversion price of Series C Preferred Stock is subject to anti-dilution adjustments and can be reduced to the lower of the original conversion price or the common stock's closing price on the registration statement's effective date, subject to a $0.65 floor.
• Federal regulatory activity in November 2025 poses a significant threat to the hemp industry and the company's revenue bases, with no assurances that mitigating legislation (CSRA) will be enacted.

Future Outlook

The company anticipates continued momentum in its direct-to-consumer and wholesale businesses, with further growth expected for the Oasis brand. Management is implementing nearly $200,000 in corporate overhead savings in early 2026. The future impact of federal regulatory actions on the hemp industry remains uncertain, with the potential for the Cannabinoid Safety and Regulation Act to mitigate negative effects if enacted.

Management Comments

• "Managements efforts to drive shareholder value during 2025 were focused in two areas: (i) deliver positive earnings through a combination of optimizing our product portfolio, rationalizing our cost structure, and growing revenue and (ii) simplifying our capital structure."
• "During fiscal 2025, we made progress on strengthening the business. We were able to essentially maintain our revenue base and we continued to reduce our GAAP operating loss from a $3.3 million loss during fiscal 2024 to $2.1 million during fiscal 2025."
• "We accomplished this while still focusing on disciplined cost control, rebuilding our marketing team and launching into the exciting hemp derived THC beverage category with our brand Oasis."
• "During fiscal 2025, we were successful in cleaning up our capital structure and, at our annual meeting in April 2025, we secured sufficient votes to convert our Series A Convertible Preferred and outstanding accrued preferred dividends into approximately 91% of the Companys outstanding common stock."
• "We are now back in compliance with the NYSE Americans continued listing standards and our non-compliance status has been removed."
• "cbdMD believes trends from late 2025 are continuing in the first quarter of 2026. We are seeing momentum in our direct-to-consumer business, wholesale is trending up and we added additional Oasis distribution during the quarter."
• "In addition, we have identified nearly $200,000 in corporate overhead savings that will be implemented during early 2026 with insurance renewals and professional fees leading the way."

Industry Context

The company operates in the evolving CBD and hemp-derived product market, which is experiencing significant regulatory challenges at both state and federal levels. The introduction of the Cannabinoid Safety and Regulation Act (CSRA) by Senator Wyden highlights the industry's efforts to establish a clearer regulatory framework and mitigate potential adverse impacts from federal actions. The company's expansion into the hemp-derived THC beverage category with its Oasis brand reflects a trend towards diversification within the broader cannabis and wellness industry, targeting high-growth segments despite initial P&L drag from investment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the conversion of Series B and Series C Preferred Stock, options, and warrants. The company will not receive proceeds from this resale. Regaining NYSE American compliance is positive for listing stability, but the 'going concern' warning remains a significant concern.
• Employees/Management: Executive compensation details are provided, including a new employment agreement for CEO/CFO T. Ronan Kennedy with increased salary and equity awards, aligning incentives.
• Customers: Continued focus on product portfolio optimization and the launch of new brands like Oasis and ATRx Labs aims to enhance product offerings and customer experience.
• Creditors: The 'going concern' explanatory paragraph in the auditor's report could raise concerns, although recent capital raises (Series B, Series C, ELOC) provide some liquidity.

Next Steps

• The registration statement must become effective before the Selling Shareholders can offer and sell the registered shares.
• The company plans to implement nearly $200,000 in corporate overhead savings during early 2026.
• Continued efforts to grow the Oasis brand and expand its distribution network.
• Monitoring and potential advocacy for the enactment of the Cannabinoid Safety and Regulation Act (CSRA) to address federal regulatory threats.
• Shareholder approval may be required for conversions of Series C Preferred Stock that would exceed 19.99% of the total common stock outstanding immediately prior to the Purchase Agreements.

Key Dates

Recommendation

This filing is primarily a procedural registration statement for the resale of shares by existing investors, not a new capital raise by the company for its operations. While the company has shown progress in reducing operating losses and improving its capital structure, the 'going concern' qualification from its auditor and significant regulatory headwinds in the hemp industry present ongoing risks. The potential for substantial dilution from the conversion of preferred stock and other equity instruments also weighs on future share price performance. Given the mixed signals and the procedural nature of this specific filing, a 'hold' recommendation is appropriate, advising investors to monitor operational execution and regulatory developments closely.

Keywords

cbdMD, YCBD, SEC Filing, S-1, Common Stock, Preferred Stock, Series C Preferred Stock, Resale, Cannabidiol, CBD, Hemp, NYSE American, Dilution, Regulatory Risk, Going Concern, Capital Structure, Oasis Brand, ATRx Labs, Paw CBD, Bluebird Botanicals, Functional Mushrooms, Cannabinoid Safety and Regulation Act